[Clinical experience with sustained release cephalexin (X-6437) (author's transl)]

Area of Science:

• Pediatric infectious diseases
• Pharmacology and pharmacokinetics
• Antibiotic therapy

Context:

• Cephalexin is a widely used antibiotic for bacterial infections.
• Developing sustained-release formulations aims to improve patient compliance and therapeutic outcomes.
• Pediatric dosing and administration present unique challenges in antibiotic therapy.

Purpose:

• To evaluate the effectiveness and safety of oral sustained release cephalexin (S-6437) in pediatric patients.
• To assess the tolerability and convenience of the S-6437 formulation in children.
• To determine the overall efficacy ratio of S-6437 in a pediatric cohort.

Summary:

• A study involving 24 pediatric patients assessed oral sustained release cephalexin (S-6437) at a daily dose of approximately 60 mg/kg, divided into two administrations.
• The overall effectiveness ratio was 69.6%, with 16 patients showing good to very good responses.
• No significant side effects were observed, and the twice-daily dosing was found to be convenient and well-tolerated by most children.

Impact:

• Sustained release cephalexin (S-6437) offers a promising therapeutic option for pediatric infections, balancing efficacy with improved convenience.
• The favorable safety profile and ease of administration support its use in pediatric populations.
• This formulation may enhance treatment adherence and clinical outcomes in children requiring cephalexin therapy.